15-min delayed · Sep 4, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Rani Therapeutics Holdings Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $5.00 to $11.00 (about 2.2x), a sign of real disagreement on valuation. The average target of $8.00 sits 825% above the current $0.87. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.05 next quarter toward $-0.19 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Strong Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Rani Therapeutics Holdings Inc.
As of Sep, 4 of 4 firms rate RANI a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RANI EPS & revenue forecast
EPS · NEXT QUARTER
$-0.05
Range $-0.06 – $-0.04 · 3 analysts · -29% YoY
Next period, 3 analysts expect Rani Therapeutics Holdings Inc to earn $-0.05 a share (range $-0.06 – $-0.04), versus $-0.07 a year earlier. Full-year consensus is $-0.17, growing to $-0.19 the year after.
REVENUE · NEXT QUARTER
$1.6M
Range $0 – $2.9M · 3 analysts · +8% YoY
Revenue is expected to reach $1.6M (range $0 – $2.9M), +7.6% year-over-year. Full-year consensus is $6.3M, rising to $6.6M next year.
Top analysts covering Rani Therapeutics Holdings Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RANI.
#1
Mitchell Kapoor
HC Wainwright & Co. · Rank #193
Buy
$9.00+940.1% to target
Overall win rate
34%
+ Follow
#2
BF
Brandon Folkes
HC Wainwright & Co. · Rank #221
Buy
$11.00+1171.2% to target
Overall win rate
42%
+ Follow
#3
Andreas Argyrides
Oppenheimer · Rank #242
Buy
$4.00+362.3% to target
Overall win rate
45%
+ Follow
#4
Raghuram Selvaraju
HC Wainwright & Co. · Rank #312
Buy
$9.00+940.1% to target
Overall win rate
36%
+ Follow
#5
EN
Edward Nash
Canaccord Genuity
Buy
$5.00+477.8% to target
Coverage
—
+ Follow
RANI stock forecast FAQ
What is RANI's average 12-month price target?+
The 4 analysts with a live target average $8.00 for Rani Therapeutics Holdings Inc over the next 12 months, ranging from a $11.00 high to a $5.00 low.
Is RANI stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RANI?+
The Street-high target is $11.00 (HC Wainwright & Co.), and the Street-low is $5.00 (Canaccord Genuity). The average of all 4 active targets is $8.00.
How many Wall Street analysts cover RANI?+
4 analysts have an active rating on Rani Therapeutics Holdings Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering RANI?+
Among analysts who currently cover RANI, Mitchell Kapoor of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #193). Their current call is Buy with a $9.00 target.
What is Rani Therapeutics Holdings Inc's projected EPS for next quarter?+
The consensus estimate is $-0.05 per share (range $-0.06 – $-0.04) across 3 analysts. Full-year EPS is projected at $-0.17, rising to $-0.19 the following year.
How much revenue is Rani Therapeutics Holdings Inc expected to report next quarter?+
Consensus revenue is $1.6M (range $0 – $2.9M). Full-year revenue is projected at $6.3M, growing to $6.6M next year.
Have analysts been upgrading or downgrading RANI lately?+
As of Sep, 4 of 4 firms rate RANI a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RANI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Chardan Capital
